

Pharmacy & Therapeutics Committee Schedule

Meetings will be held virtually and the agenda containing the meeting login information is posted approximately ten days prior to the meeting. The therapeutic drug classes are tentatively scheduled and subject to change. Please review the Prime Manufacturer Letter located on the [Prime Therapeutics](#) website under the Arizona section for the final list of therapeutic drug classes to be reviewed at the meeting.

P&T Committee Schedule	
Date	Draft Class Review – Subject to Change
January 13, 2026	<p>Non-Supplemental Rebate Class Review:</p> <ul style="list-style-type: none"> • Antidepressants, Other • Antidepressants, SSRIs • Antivirals, Topical • Bladder Relaxant Preparations • Bone Resorption Suppression and Related Agents • Bronchodilators, Beta Agonists • Enzyme Replacement, Gaucher Disease • Hypoglycemics, Metformins • Hypoglycemics, SGLT2s • Immune Globulins • Oncology, Oral – Hematologic • Ophthalmics, Anti-inflammatory/ Immunomodulators • Oral and Inhaled Pulmonary Arterial Hypertension Agents • Otic Antibiotics • Thrombopoiesis Stimulating Agents • Ulcerative Colitis <p>Supplemental Rebate Class Review:</p> <ul style="list-style-type: none"> • Hereditary Angioedema Treatments • Pituitary Suppressive Agents, LHRH
May 19, 2026	<p>Supplemental Rebate Classes Review:</p> <ul style="list-style-type: none"> • Antibiotics, Inhaled • Antimigraine Agents, Other • Antipsychotics, Atypical Long-Acting Injectable • Antipsychotics, Oral Atypical (2nd Gen Only) • Colony Stimulating Factors • COPD Agents • Cytokine and CAM Antagonists • GI Motility, Chronic • Glucagon Agents • Growth Hormone • Hepatitis C Agents • Hypoglycemics, Incretin Mimetics/Enhancers • Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma) • Movement Disorders • Multiple Sclerosis Agents • Opioid Dependence Treatments

	<ul style="list-style-type: none"> • Pancreatic Enzymes • Uterine Disorder Treatments
October 7, 2026	<p>Non-Supplemental Repeat Classes Review:</p> <ul style="list-style-type: none"> • Antimigraine Agents-Triptans • Leukotriene Modifiers • Phosphate Binders • Sedative Hypnotics • Topical Steroids by Potency (low, medium, high, very high) • Antifungals-Oral • Antifungals- Topicals • Beta Blockers • BPH Treatments • Calcium Channel Blockers • HIV-AIDS • Movement Disorders
January 26, 2027	<p>Non-Supplemental Rebate Class Review:</p> <ul style="list-style-type: none"> • Androgenic Agents • Antidepressants, Other • Antidepressants, SSRIs • Antivirals, Topical • Bone Resorption Suppression and Related Agents • Bronchodilators, Beta Agonists • Colony Stimulating Factors • Enzyme Replacement, Gaucher Disease • Erythropoiesis Stimulating Proteins • Hypoglycemics, Alpha Glucosidase Inhibitors • Hypoglycemics, Metformins • Hypoglycemics, SGLT2s • Immune Globulins • Oncology, Oral – Hematologic • Ophthalmics, Anti-inflammatory/ Immunomodulators • Oral and Inhaled Pulmonary Arterial Hypertension Agents • Otic Antibiotics • Thrombopoiesis Stimulating Agents • Ulcerative Colitis

For additional information on AHCCCS Pharmacy & Therapeutics (P&T) Committee public testimony and class reviews visit the [Prime Therapeutics](#) website.